In short
A new drug called LEO 138559, which is a humanised IgG1 monoclonal antibody targeting the interleukin 22 receptor subunit alpha, is being studied in clinical trials for the treatment of moderate-to-severe atopic dermatitis. This article discusses the ongoing research, including the drug's potential efficacy, safety, and administration methods for patients with this challenging skin condition.
At a glance
- Drug Name
- LEO 138559 (Humanised IgG1 Monoclonal Antibody Against Interleukin 22 Receptor Subunit Alpha)
- Condition Studied
- Moderate-to-severe Atopic Dermatitis
- Trial Phase
- Phase 2b
- Main Objective
- Compare efficacy of 4 different dosage regimens with placebo
- Administration Method
- Subcutaneous injection
- Treatment Duration
- 14 weeks
- Primary Endpoint
- Percent change in EASI score from baseline to Week 16
- Key Inclusion Criteria
- Adults 18-75 years, AD diagnosis, inadequate response to previous treatments, EASI score ≥16, vIGA-AD score ≥3, BSA ≥10%
- Key Exclusion Criteria
- Recent infections, certain prior treatments, pregnancy, hepatitis B/C, HIV, active tuberculosis
What is LEO 138559?
LEO 138559 is a new medication being studied for the treatment of moderate-to-severe atopic dermatitis (AD), also known as eczema. It is a humanized IgG1 monoclonal antibody that targets the interleukin 22 receptor subunit alpha. In simpler terms, it's a specially designed protein that aims to reduce inflammation in the skin by blocking a specific part of the immune system.
How Does LEO 138559 Work?
LEO 138559 works by targeting a specific part of the immune system involved in atopic dermatitis. It blocks the interleukin 22 receptor, which is believed to play a role in the inflammation and skin symptoms associated with AD. By doing this, the medication aims to reduce the severity of eczema symptoms and improve the overall condition of the skin.
Clinical Trial Details
A clinical trial is currently underway to evaluate the effectiveness and safety of LEO 138559 for adults with moderate-to-severe atopic dermatitis. This is a Phase 2b trial, which means it's focused on finding the right dose of the medication.
The main goal of this trial is to compare four different dosing regimens of LEO 138559 with a placebo (a substance with no active medication) to see which works best for people with moderate-to-severe AD.
Who Can Participate in the Trial?
The trial is looking for adults aged 18-75 who have had atopic dermatitis for at least one year. Participants need to have moderate-to-severe AD, which is determined by several factors:
- An EASI score (a measure of eczema severity) of 16 or higher
- A vIGA-AD score (another measure of AD severity) of 3 or higher
- At least 10% of their body surface area affected by AD
- A Worst Itch score of 4 or higher
Participants should also have a history of not responding well to topical treatments like corticosteroids or having side effects from these treatments.
Treatment Regimens
The trial is testing four different dosing regimens of LEO 138559, all given as a subcutaneous injection (an injection under the skin):
- Dose A given weekly for the first four weeks, then every two weeks
- Dose B given weekly for the first three weeks, then every two weeks
- Dose A given at weeks 0 and 2, then Dose C every two weeks
- Dose C given at weeks 0 and 2, then Dose D every two weeks
Some participants will receive a placebo instead of the active medication. The treatment period lasts for 16 weeks.
Potential Benefits
If successful, LEO 138559 could provide a new treatment option for people with moderate-to-severe atopic dermatitis who haven't responded well to other treatments. The main goal is to reduce the severity of AD symptoms, which could lead to improved quality of life for patients.
Safety Considerations
As with any new medication, safety is a key concern. The trial will closely monitor participants for any side effects or adverse reactions. People with certain conditions, such as active infections, hepatitis B or C, HIV, or tuberculosis, are not eligible to participate in the trial for safety reasons.
It's important to note that LEO 138559 is still in the testing phase, and more research is needed to fully understand its effectiveness and safety profile.